Intelligent Bio Solutions Q4 revenue up 16% YoY to $844K; progress on FDA 510(k) for U.S. market

INTELLIGENT BIO SOLUTIONS INC.

2025-FY EPS reported -$2.00 revenue$3,052,532

Q4 FY2025 revenue $843,884 (+16% YoY); cartridge sales up 24% YoY.
Added 115 new accounts in FY2025; active base >450 across 24 countries with 18 distributors.
FDA 510(k) submission in progress for opiate test system; seeking U.S. clearance beyond Forensic Use Only.
Operational improvements: multilingual system, HubSpot CRM, new U.S. patent; accounting system upgrade underway.
Net loss or EPS not disclosed; company reports 'reduced net loss' but no specific figures.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.